These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 34255035

  • 1. Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability.
    Wu M, Chen W, Miao M, Jin Q, Zhang S, Bai M, Fan J, Zhang Y, Zhang A, Jia Z, Huang S.
    Clin Sci (Lond); 2021 Jul 30; 135(14):1707-1726. PubMed ID: 34255035
    [Abstract] [Full Text] [Related]

  • 2. Pathophysiology of unilateral ischemia-reperfusion injury: importance of renal counterbalance and implications for the AKI-CKD transition.
    Polichnowski AJ, Griffin KA, Licea-Vargas H, Lan R, Picken MM, Long J, Williamson GA, Rosenberger C, Mathia S, Venkatachalam MA, Bidani AK.
    Am J Physiol Renal Physiol; 2020 May 01; 318(5):F1086-F1099. PubMed ID: 32174143
    [Abstract] [Full Text] [Related]

  • 3. FIH-1-modulated HIF-1α C-TAD promotes acute kidney injury to chronic kidney disease progression via regulating KLF5 signaling.
    Li ZL, Wang B, Lv LL, Tang TT, Wen Y, Cao JY, Zhu XX, Feng ST, Crowley SD, Liu BC.
    Acta Pharmacol Sin; 2021 Dec 01; 42(12):2106-2119. PubMed ID: 33658705
    [Abstract] [Full Text] [Related]

  • 4. Tubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition.
    Lok SWY, Yiu WH, Zou Y, Xue R, Li H, Ma J, Chen J, Chan LYY, Lai KN, Tang SCW.
    Nephrol Dial Transplant; 2023 Sep 29; 38(10):2232-2247. PubMed ID: 36914214
    [Abstract] [Full Text] [Related]

  • 5. Endoplasmic reticulum stress is activated in post-ischemic kidneys to promote chronic kidney disease.
    Shu S, Zhu J, Liu Z, Tang C, Cai J, Dong Z.
    EBioMedicine; 2018 Nov 29; 37():269-280. PubMed ID: 30314894
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
    Yang Y, Yu X, Zhang Y, Ding G, Zhu C, Huang S, Jia Z, Zhang A.
    Clin Sci (Lond); 2018 Apr 16; 132(7):825-838. PubMed ID: 29581249
    [Abstract] [Full Text] [Related]

  • 8. ISG15 accelerates acute kidney injury and the subsequent AKI-to-CKD transition by promoting TGFβR1 ISGylation.
    Cui N, Liu C, Tang X, Song L, Xiao Z, Wang C, Wu Y, Zhou Y, Peng C, Liu Y, Zheng L, Liu X, Huang K, Chen H.
    Theranostics; 2024 Apr 16; 14(11):4536-4553. PubMed ID: 39113797
    [Abstract] [Full Text] [Related]

  • 9. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
    Miao AF, Liang JX, Yao L, Han JL, Zhou LJ.
    Ren Fail; 2021 Dec 16; 43(1):803-810. PubMed ID: 33966598
    [Abstract] [Full Text] [Related]

  • 10. NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury.
    Xie ZY, Dong W, Zhang L, Wang MJ, Xiao ZM, Zhang YH, Shi WX, Huang Y, Yang Y, Li CL, Fu L, Zhao XC, Li RZ, Li ZL, Chen YH, Ye ZM, Liu SX, Dong Z, Liang XL.
    Acta Pharmacol Sin; 2022 Aug 16; 43(8):2081-2093. PubMed ID: 34937917
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hypoxia inducible factor stabilization improves defective ischemia-induced angiogenesis in a rodent model of chronic kidney disease.
    Schellinger IN, Cordasic N, Panesar J, Buchholz B, Jacobi J, Hartner A, Klanke B, Jakubiczka-Smorag J, Burzlaff N, Heinze E, Warnecke C, Raaz U, Willam C, Tsao PS, Eckardt KU, Amann K, Hilgers KF.
    Kidney Int; 2017 Mar 16; 91(3):616-627. PubMed ID: 27927598
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The hypoxia-inducible factor-α prolyl hydroxylase inhibitor FG4592 ameliorates renal fibrosis by inducing the H3K9 demethylase JMJD1A.
    Ike T, Doi S, Nakashima A, Sasaki K, Ishiuchi N, Asano T, Masaki T.
    Am J Physiol Renal Physiol; 2022 Nov 01; 323(5):F539-F552. PubMed ID: 36074918
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease.
    Faivre A, Katsyuba E, Verissimo T, Lindenmeyer M, Rajaram RD, Naesens M, Heckenmeyer C, Mottis A, Feraille E, Cippà P, Cohen C, Longchamp A, Allagnat F, Rutkowski JM, Legouis D, Auwerx J, de Seigneux S.
    Nephrol Dial Transplant; 2021 Jan 01; 36(1):60-68. PubMed ID: 33099633
    [Abstract] [Full Text] [Related]

  • 19. New mouse model of chronic kidney disease transitioned from ischemic acute kidney injury.
    Wei J, Zhang J, Wang L, Jiang S, Fu L, Buggs J, Liu R.
    Am J Physiol Renal Physiol; 2019 Aug 01; 317(2):F286-F295. PubMed ID: 31116604
    [Abstract] [Full Text] [Related]

  • 20. A short treatment with resveratrol after a renal ischaemia-reperfusion injury prevents maladaptive repair and long-term chronic kidney disease in rats.
    Martínez-Rojas MÁ, Balcázar H, Ponce-Nava MS, González-Soria I, Marquina-Castillo B, Pérez-Villalva R, Bobadilla NA.
    J Physiol; 2024 Apr 01; 602(8):1835-1852. PubMed ID: 38529522
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.